MiNK Therapeutics, Inc. (a Delaware corporation) Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 12th, 2021 Company Industry Jurisdiction
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 12th, 2021 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [_________], 2021, between MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), and [______] (“Indemnitee”).
MINK THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledOctober 12th, 2021 Company IndustryThis agreement (this “Agreement”) evidences a stock option granted by MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
MINK THERAPEUTICS, INC. NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledOctober 12th, 2021 Company IndustryThis agreement (this “Agreement”) evidences a stock option granted by MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
AMENDMENT TO CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 12th, 2021 Company Industry JurisdictionTHIS AMENDMENT TO CONVERTIBLE PROMISSORY NOTE (this “Amendment”), dated as of September 29, 2021 (the “Effective Date”), is made between MiNK Therapeutics, Inc., a Delaware corporation (f/k/a AgenTus Therapeutics, Inc.; the “Company”) and Agenus Inc., a Delaware corporation (the “Holder”; together with the Company, the “Parties”).
MINK THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • October 12th, 2021 • MiNK Therapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledOctober 12th, 2021 Company IndustryThis agreement (this “Agreement”) evidences a grant (the “Award”) of Restricted Stock Units (“RSUs”) by MiNK Therapeutics, Inc., a Delaware corporation (the “Company”), to the individual named above (the “Participant”), pursuant to and subject to the terms of the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.